Physician profile

Aron Rubin

Pulmonary Disease · Brooklyn, NY

NPI 1396788956

$16,931.05

in general payments reported to CMS, 2019-2025

32 companies · $3,323 in 2025

The $3,323 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,255.04
Education$380.42

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $3,169.28 2019-2025 Tezspire, Fasenra, Airsupra
Glaxosmithkline, LLC. $2,734.30 2019-2025 Trelegy Ellipta, Nucala
Boehringer Ingelheim Pharmaceuticals, INC. $1,921.24 2019-2025 Spiriva Respimat, Ofev, Stiolto Respimat
Genzyme Corporation $1,877.93 2019-2025
Regeneron Healthcare Solutions, INC. $1,459.17 2020-2025 Dupixent
Mylan Specialty L.P. $1,196.40 2019-2024 Yupelri
Viatris Specialty LLC $607.31 2025 Yupelri
Philips North America LLC $555.40 2020-2025 Vest Therapy Und, (Ak6) Vest Therapy
Insmed, INC. $411.69 2020-2025 Arikayce, Brinsupri
Genentech USA, INC. $400.37 2019-2022
Verona Pharma, INC. $388.46 2025 Ohtuvayre
Regeneron Pharmaceuticals, INC. $377.84 2020-2024 Dupixent
E.R. Squibb & Sons, L.L.C. $328.58 2019-2024 Eliquis, Camzyos
Sanofi-Aventis U.S. LLC $238.69 2021-2025
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $218.94 2021-2023 Xifaxan, Trulance
Show all 32 companies
CompanyGeneral paymentsYearsTop products
Electromed, INC. $179.53 2021-2025 Smartvest
Amgen INC. $142.61 2022-2024 Tezspire
Actelion Pharmaceuticals US, INC. $106.50 2022
Inogen, INC. $99.59 2023 Inogen One G5 Oxygen Concentrator - Bluetooth
Optinose US, INC. $92.85 2019-2020
Amarin Pharma, INC. $75.47 2019-2023
Takeda Pharmaceuticals U.S.A., INC. $75.00 2024
Novartis Pharmaceuticals Corporation $52.08 2019
Horizon Therapeutics Plc $36.62 2022
Sunovion Pharmaceuticals INC. $34.02 2019
Janssen Pharmaceuticals, INC $31.04 2019
Mallinckrodt Hospital Products INC. $28.00 2021
Paratek Pharmaceuticals, INC. $23.72 2023 Nuzyra
Pfizer INC. $22.00 2019
United Therapeutics Corporation $18.08 2021
Arbor Pharmaceuticals, INC. $16.66 2019
Circassia INC. $11.68 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Aron Rubin

$16,931.05

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals Lp
Context
The $3,323 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/18222/aron-rubin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.